SCHEMBL24600350

SCHEMBL24600350

Cc1cc(C)cc(-n2cc(Oc3c(Cl)cc(-n4nc(C#N)c(=O)[nH]c4=O)cc3Cl)ccc2=O)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ THRA P10827 16/20 0.54
▸ THRB P10828 16/20 0.54
▸ CYP2C9 P11712 2/20 0.53
▸ CYP2C8 P10632 1/20 0.53
▸ NPC1 O15118 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ NPBWR1 P48145 2/20 0.38
▸ MCHR1 Q99705 1/20 0.38
▸ UGT1A1 P22309 1/20 0.37
▸ ABCG2 Q9UNQ0 1/20 0.37
▸ SLCO1B1 Q9Y6L6 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24600362 0.93 THRA (0.54) THRATHRBCYP2C9CYP2C8NPC1
SCHEMBL24600238 0.92 THRA (0.52) THRATHRBCYP2C9CYP2C8NPC1
SCHEMBL24600240 0.89 THRB (0.52) THRATHRBCYP2C9CYP2C8NPC1
SCHEMBL24600247 0.89 THRB (0.54) THRATHRBCYP2C9CYP2C8NPC1
SCHEMBL24600242 0.88 THRB (0.51) THRATHRBCYP2C9CYP2C8NPC1
SCHEMBL24600345 0.87 THRB (0.52) THRATHRBCYP2C9CYP2C8NPC1
SCHEMBL28664590 0.87 THRB (0.52) THRATHRBCYP2C9CYP2C8NPC1
SCHEMBL24600311 0.87 THRB (0.52) THRATHRBCYP2C9CYP2C8NPC1
SCHEMBL24600272 0.86 THRB (0.51) THRATHRBCYP2C9CYP2C8NPC1
SCHEMBL24600251 0.86 THRA (0.51) THRATHRBCYP2C9CYP2C8NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109863-A1 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF KPC PHARMACEUTICALS, INC (CN) 2024-04-04 — — US disclosed
EP-4273139-A1 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF KPC Pharmaceuticals, Inc. (CN) 2023-11-08 — — EP disclosed
EP-4273139-A1 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF KPC Pharmaceuticals, Inc. (CN) 2023-11-08 — — EP disclosed
WO-2022143574-A1 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF 昆药集团股份有限公司 2022-07-07 — — WO disclosed
WO-2022143574-A1 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF 昆药集团股份有限公司 2022-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109863-A1 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF PTH1R, MC2R, TSHR THRA 18/4885THRB 16/4885CYP2C9 1082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback